Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AMLX

Amylyx Pharmaceuticals Inc

May 10 • 04:00PM ET

1.75

Dollar change -0.13
Percentage change -7.14	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBK IWM VXF IWO IBB VTWO VHT SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	30.75%	Shs Outstand	67.71M	Perf Week	-13.55%
Market Cap	119.36M	Forward P/E	-	EPS next Y	-1.23	Insider Trans	-0.13%	Shs Float	47.42M	Perf Month	-23.36%
Income	-71.09M	PEG	-	EPS next Q	-0.73	Inst Own	87.13%	Short Float	17.96%	Perf Quarter	-89.13%
Sales	398.00M	P/S	0.30	EPS this Y	-460.48%	Inst Trans	32.39%	Short Ratio	2.42	Perf Half Y	-90.25%
Book/sh	4.77	P/B	0.37	EPS next Y	51.25%	ROA	-17.23%	Short Interest	8.51M	Perf Year	-93.94%
Cash/sh	5.49	P/C	0.32	EPS next 5Y	-	ROE	-21.00%	52W Range	1.70 - 30.50	Perf YTD	-88.08%
Dividend Est.	-	P/FCF	7.73	EPS past 5Y	-	ROI	-21.82%	52W High	-94.25%	Beta	-0.65
Dividend TTM	-	Quick Ratio	4.48	Sales past 5Y	2300.59%	Gross Margin	65.39%	52W Low	3.24%	ATR (14)	0.24
Dividend Ex-Date	Mar 28, 2018	Current Ratio	4.48	EPS Y/Y TTM	32.69%	Oper. Margin	-20.42%	RSI (14)	25.39	Volatility	7.70% 7.45%
Employees	384	Debt/Eq	0.01	Sales Y/Y TTM	324.95%	Profit Margin	-17.86%	Recom	2.71	Target Price	4.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-7986.04%	Payout	0.00%	Rel Volume	0.45	Prev Close	1.89
Sales Surprise	-9.91%	EPS Surprise	-43650.00%	Sales Q/Q	24.10%	Earnings	May 09 BMO	Avg Volume	3.51M	Price	1.75
SMA20	-9.61%	SMA50	-60.42%	SMA200	-87.48%	Trades		Volume	1,589,727	Change	-7.14%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)
09:00AM	Loading…
May-02-24 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-30-24 12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
Apr-10-24 03:14PM	Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder (Benzinga) -7.87%
09:00AM	Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome (Business Wire)
Apr-08-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 (Business Wire)
Apr-04-24 01:20PM	Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% (Zacks)
10:05AM	ALS drug will be pulled from US market after study showed patients didn't benefit (Associated Press Finance)
07:52AM	UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets (Reuters)
07:43AM	Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market (Barrons.com)
07:07AM	Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets (Reuters)
07:00AM	Loading…
07:00AM	Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy (Business Wire)
06:09AM	Amylyx to pull ALS drug from market in rare move (BioPharma Dive)
Apr-03-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire)
Apr-01-24 07:30PM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Mar-27-24 07:36AM	European study finds popular ALS drug ineffective (BioPharma Dive) +5.11%
Mar-25-24 02:33PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace) -7.85%
09:00AM	Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors (Business Wire)
Mar-13-24 10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx (PR Newswire)
09:03AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-12-24 07:55AM	After surprise trial failure, ALS doctors brace for one less treatment option (BioPharma Dive) -9.47%
Mar-11-24 12:34PM	Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82% (Zacks) +13.10%
07:45AM	Amylyx CEOs look for a path forward following major setback (BioPharma Dive)
Mar-10-24 08:00AM	Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn. (The Wall Street Journal)
Mar-08-24 06:27PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -82.29%
04:05PM	Loading…
04:05PM	Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure (Investor's Business Daily)
11:30AM	Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work (Associated Press Finance)
10:20AM	Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future (Barrons.com)
10:12AM	Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test (Investor's Business Daily)
09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
09:26AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
07:07AM	Amylyx's ALS drug fails in late-stage confirmatory study (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire)
02:05AM	Amylyx ALS drug fails crucial study, putting companys future in doubt (BioPharma Dive)
Feb-27-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) +8.20%
Feb-26-24 11:39AM	AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline (GlobeNewswire)
Feb-25-24 06:30AM	7 Oversold Russell 2000 Stocks to Add to Your February Buy List (InvestorPlace)
Feb-23-24 04:05PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
10:30AM	AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options (GlobeNewswire)
10:10AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Amylyx Pharmaceuticals, Inc. (Business Wire)
05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX (PR Newswire)
Feb-22-24 06:57PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire) +21.10%
04:10PM	Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter (Investor's Business Daily)
08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates (Zacks)
07:35AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Robust Revenue Growth and Net Income for Full Year 2023 (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) -6.11%
Feb-19-24 12:40PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Feb-15-24 04:05PM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (Business Wire)
02:13PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
09:00AM	Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference (Business Wire)
Feb-13-24 09:16PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -7.94%
12:58PM	Get Rich Quick With These 3 Biotech Stocks to Buy Now (InvestorPlace)
Feb-12-24 08:09PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
11:09AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Feb-08-24 09:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jan-26-24 03:57PM	3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 (InvestorPlace)
Jan-21-24 01:16PM	3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-14-24 12:54PM	7 Healthcare Stocks Taking Medicine to the Next Level (InvestorPlace)
Jan-05-24 05:34AM	2 Biotech Stocks With Huge Catalysts in 2024 (Motley Fool)
Dec-26-23 07:02PM	5 Best IPO Stocks to Buy Heading into 2024 (Insider Monkey)
08:48AM	Is Amylyx (AMLX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 09:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP) (Business Wire)
Dec-11-23 08:36AM	Implied Volatility Surging for Amylyx (AMLX) Stock Options (Zacks)
Dec-04-23 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS (Business Wire)
Nov-29-23 05:15PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19%
Nov-28-23 08:48AM	3 Top-Rated Biotech Stocks That Analysts Are Loving Now (InvestorPlace)
07:00AM	Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer (Business Wire)
Nov-27-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND (Business Wire)
Nov-21-23 09:00AM	Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-23 11:59AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 12:26AM	Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 05:04PM	Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024 (Investor's Business Daily) -31.89%
12:12PM	Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles (Investor's Business Daily)
08:05AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue Growth (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-04-23 12:16PM	5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-02-23 10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks) +5.38%
09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023 (Business Wire)
Oct-19-23 09:00AM	Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks)
Oct-13-23 08:26AM	UPDATE 1-EU regulator declines to recommend Amylyx' ALS drug (Reuters)
07:55AM	EU regulator declines to recommend Amylyx' ALS therapy (Reuters)
07:45AM	Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process (Business Wire)
Oct-11-23 08:07AM	PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last? (Zacks)
Oct-10-23 09:45AM	2 Incredible Growth Stocks Near 52-Week Lows to Buy Now (Motley Fool)
09:12AM	Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control (Business Wire)
Oct-05-23 05:26PM	Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France (Business Wire)
Oct-02-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting (Business Wire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
02:54AM	14 Best Depressed Stocks To Buy Now (Insider Monkey)
Sep-20-23 09:02AM	Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-05-23 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire) -5.41%
Aug-28-23 11:53PM	3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List (InvestorPlace)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klee Justin B.	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	2,959,308	Mar 07 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	3,023,002	Mar 07 04:05 PM
FRATES JAMES M	Chief Financial Officer	Mar 05 '24	Sale	18.73	1,792	33,560	134,784	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Mar 05 '24	Sale	18.73	1,540	28,841	81,372	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 23 '24	Sale	18.76	2,838	53,231	46,245	Feb 27 05:59 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,836,776	Jan 11 05:11 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,900,470	Jan 11 05:10 PM
Yeramian Patrick D	Chief Medical Officer	Jan 09 '24	Sale	16.33	2,812	45,915	205,605	Jan 11 05:04 PM
FRATES JAMES M	Chief Financial Officer	Jan 09 '24	Sale	16.33	2,716	44,347	112,035	Jan 11 05:11 PM
Olinger Margaret	Chief Commercial Officer	Dec 27 '23	Option Exercise	0.37	25,000	9,250	276,108	Dec 29 04:07 PM
Firestone Karen	Director	Dec 15 '23	Buy	14.97	4,000	59,880	5,000	Dec 19 04:37 PM
Cohen Joshua B	Co-Chief Executive Officer	Nov 16 '23	Option Exercise	1.57	63,694	100,000	2,906,311	Nov 20 08:20 PM
FRATES JAMES M	Chief Financial Officer	Aug 23 '23	Option Exercise	6.88	18,165	124,975	106,341	Aug 24 04:15 PM
Mazzariello Gina	Chief Legal Officer	Aug 15 '23	Sale	20.88	6,164	128,686	49,083	Aug 17 04:35 PM
Olinger Margaret	Chief Commercial Officer	Jul 12 '23	Option Exercise	0.37	20,000	7,400	251,108	Jul 14 04:20 PM
FRATES JAMES M	Chief Financial Officer	May 16 '23	Option Exercise	6.88	32,500	223,600	88,176	May 18 08:54 PM
FRATES JAMES M	Chief Financial Officer	May 16 '23	Sale	26.94	32,500	875,451	55,676	May 18 08:54 PM
Yeramian Patrick D	Chief Medical Officer	May 15 '23	Option Exercise	5.68	11,965	67,991	220,382	May 17 04:58 PM
Yeramian Patrick D	Chief Medical Officer	May 15 '23	Sale	29.03	11,965	347,358	208,417	May 17 04:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMLX

Amylyx Pharmaceuticals Inc

Upgrade your FINVIZ experience